David J. Kwiatkowski, MD, PhD, on Clinical Implications of Neoadjuvant Atezolizumab for Resectable Non–Small Cell Lung Cancer

Posted: Sunday, June 2, 2019

David J. Kwiatkowski, MD, PhD, of Brigham and Women’s Hospital and Dana-Farber Cancer Institute, discusses the clinical implications of later lines of therapy if a checkpoint inhibitor is used in the neoadjuvant setting for resectable non–small cell lung cancer.